COPD Insights for Primary Care: 5 New Studies

Apnimed's first-in-class anti-apneic AD109 increases upper airway muscle tone during sleep; the company plans to file an NDA with the FDA in early 2026.

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

A smartphone-based asthma management program significantly enhanced symptom control, but may require engagement or cultural tailoring to expand the effect.

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

Research from the Karolinska Institute reveals that therapies such as dupilumab and mepolizumab may not eliminate Th2 lymphocytes, raising concerns about long-term remission.

Weight cycling significantly raises heart failure and metabolic disease risks, independent of baseline overweight, underscoring the importance of stable weight strategies.